Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience

Koonal Shah;Qing Wang;Michael F. Drummond;Anne R. Mason;Martina Garau;Adrian Towse

Contract Research from Office of Health Economics

Abstract: Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor in lower use in the UK. This Report is based on both a detailed literature review and interviews with key experts directly involved in the work of UK HTA bodies. It uncovers several important issues, including limitations in the use of QALYs for assessment of cancer therapies, the need for better integration of social value judgments in the deliberative process, and the important differences among licensing agencies, HTA bodies and companies about how best to measure effectiveness. Recommendations for addressing each issue are offered.

Keywords: Assessment; and; Appraisal; of; Oncology; Medicines:; NICE's; Approach; and; International; HTA; Experience (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2009-02-01
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/assessment-and-ap ... nd_appraisal_2-2009/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:000234

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).